Elevated circulating level of β-aminoisobutyric acid (BAIBA) in heart failure patients with type 2 diabetes receiving sodium-glucose cotransporter 2 inhibitors

Cardiovasc Diabetol. 2022 Dec 20;21(1):285. doi: 10.1186/s12933-022-01727-x.

Abstract

Aims: The mechanism by which a sodium-glucose cotransporter inhibitor (SGLT2i) induces favorable effects on diabetes and cardiovascular diseases including heart failure (HF) remains poorly understood. Metabolomics including amino acid profiling enables detection of alterations in whole body metabolism. The aim of this study was to determine whether plasma amino acid profiles are modulated by SGLT2i use in HF patients with type 2 diabetes mellitus (T2DM).

Methods: We retrospectively examined 81 HF patients with T2DM (68 ± 11 years old; 78% male). Plasma amino acid concentrations in a fasting state after stabilization of HF were determined using ultraperformance liquid chromatography. To minimize potential selection bias in the retrospective analyses, the differences in baseline characteristics between patients receiving an SGLT2i and patients not receiving an SGLT2i were controlled by using an inverse probability of treatment weighting (IPTW)-adjusted analysis.

Results: Of amino acids measurable in the present assay, plasma β-aminoisobutyric acid (BAIBA), an exercise-induced myokine-like molecule also known as 3-aminoisobutyric acid or 3-amino-2-methyproponic acid, was detected in 77% of all patients and the proportion of patients in whom plasma BAIBA was detected was significantly higher in patients receiving an SGLT2i than in patients not receiving an SGLT2i (93% vs. 67%, p = 0.01). Analyses in patients in whom plasma BAIBA was detected showed that plasma BAIBA concentration was significantly higher in patients receiving an SGLT2i than in patients not receiving an SGLT2i (6.76 ± 4.72 vs. 4.56 ± 2.93 nmol/ml, p = 0.03). In multivariate logistic regression analyses that were adjusted for age and sex, SGLT2i use was independently associated with BAIBA detection. The independent association between BAIBA and SGLT2i use remained after inclusion of body mass index, HF with reduced ejection fraction, ischemic etiology, renal function, NT-proBNP, albumin, hemoglobin, and HbA1c into the Cox proportional hazards model. When the differences in baseline characteristics between patients receiving an SGLT2i and patients not receiving an SGLT2i were controlled by using an IPTW-adjusted analysis, least squares mean of plasma BAIBA concentration was significantly higher in patients receiving an SGLT2i than in patients not receiving an SGLT2i.

Conclusion: SGLT2i use is closely associated with increased circulating BAIBA concentration in HF patients with T2DM.

Keywords: Amino acid; Diabetes mellitus; Heart failure; SGLT2; Sodium-glucose cotransporter 2 inhibitors; β-aminoisobutyric acid.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Aminoisobutyric Acids
  • Diabetes Mellitus, Type 2* / diagnosis
  • Diabetes Mellitus, Type 2* / drug therapy
  • Female
  • Glucose
  • Heart Failure* / chemically induced
  • Heart Failure* / diagnosis
  • Heart Failure* / drug therapy
  • Humans
  • Male
  • Middle Aged
  • Retrospective Studies
  • Sodium
  • Sodium-Glucose Transporter 2 Inhibitors* / adverse effects

Substances

  • 3-aminoisobutyric acid
  • Aminoisobutyric Acids
  • Sodium-Glucose Transporter 2 Inhibitors
  • Glucose
  • Sodium